FSD Pharma (NASDAQ:HUGE) Stock Rating Reaffirmed by Singular Research

Singular Research reiterated their buy-venture rating on shares of FSD Pharma (NASDAQ:HUGE) in a research note issued to investors on Tuesday morning, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma Stock Down 4.3 %

Shares of FSD Pharma stock opened at $0.35 on Tuesday. The business has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.86. The stock has a market cap of $13.97 million, a PE ratio of -0.74 and a beta of 0.71. FSD Pharma has a 12 month low of $0.34 and a 12 month high of $1.68.

FSD Pharma (NASDAQ:HUGE) last issued its earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On FSD Pharma

An institutional investor recently raised its position in FSD Pharma stock. AdvisorShares Investments LLC raised its holdings in FSD Pharma Inc. (NASDAQ:HUGE) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 270,316 shares of the company’s stock after acquiring an additional 34,679 shares during the period. AdvisorShares Investments LLC owned about 0.69% of FSD Pharma worth $249,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.24% of the company’s stock.

FSD Pharma Company Profile

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.